MDXH MDxHealth S.A.
USHealthcareAs of 2026-07-10 16:00
Why MDXH matters now
MDxHealth S.A. (MDXH) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.48 with -2.84% on the session and $24.4M in market capitalization; recent performance reads 1-month -35.30% and YTD -84.79%.
The latest financial table shown here is Q4 2025, with revenue of $54.7M, net income of $-18.8M, and EPS of $-0.37. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -5.9%.
The latest indexable market news headline is "Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $4.00; recent insider activity includes OConnell Brendan filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-2.25
P/S
0.34
EV/EBITDA
-15.74
DCF Value
$-81.71
FCF Yield
-5.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
57.7%
Operating Margin
-16.6%
Net Margin
-32.2%
ROE
403.0%
ROA
-17.7%
ROIC
-12.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $54.7M | $-18.8M | $-0.37 |
| FY 2025 | $107.9M | $-33.5M | $-0.67 |
| Q2 2025 | $26.6M | $-7.4M | $-0.30 |
| Q4 2024 | $48.1M | $-18.0M | $-0.38 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$4.00
Target (Median)
$4.00
Target Range
$4.00 - $4.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
BE
Exchange
—
Beta
0.38
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.